Story perspectives

Moderna and Merck’s Intismeran Plus Keytruda Cuts Melanoma Recurrence

8/20/2026

Summary

Story summary

Moderna and Merck announced Intismeran plus Keytruda cut melanoma recurrence in a trial.
The trial enrolled 1,137 melanoma patients receiving nine vaccine doses plus Keytruda or Keytruda alone.
Interim results met the primary goal of longer recurrence-free survival and secondary goal of reduced metastasis.
Moderna shares rose 175% to $154.48 while Merck shares gained about 11%.
Data will be presented at an international medical meeting as companies discuss regulatory filings.

1 of 1

Story summary

Moderna and Merck announced Intismeran plus Keytruda cut melanoma recurrence in a trial.
The trial enrolled 1,137 melanoma patients receiving nine vaccine doses plus Keytruda or Keytruda alone.
Interim results met the primary goal of longer recurrence-free survival and secondary goal of reduced metastasis.
Moderna shares rose 175% to $154.48 while Merck shares gained about 11%.
Data will be presented at an international medical meeting as companies discuss regulatory filings.